Skip to content

Early closure ileostomy in patients with rectal cancer (stage 2,3) who have undergone LAR surgery.

Evaluation of the results of early ileostomy closure in patients with rectal cancer (stage 2,3) who underwent LAR surgery compared to the usual method (delayed closure after the end of chemotherapy adjuvant)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201113049373N1
Enrollment
70
Registered
2021-01-02
Start date
2016-03-20
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer. Malignant neoplasm of rectum

Interventions

Intervention group: Group A includes patients who meet the inclusion criteria after receiving the second dose of adjuvant chemotherapy and two week of rest after about (8weeks of surgery) to close the

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with locally advanced rectal cancer (stage 2,3)(2) Receive neoadjuvant radiotherapy.(3) L.A.R and implantation of protective ileostomy(4) Satisfaction with premature ostomy closure

Exclusion criteria

Exclusion criteria: 1- Leak evidence of anastomosis in the study of water-soluble contrast 2- Do not start Adj chemotherapy during 2-4 weeks after the first surgery 3- Dissatisfaction with ostomy closure 4- Occurrence of systemic complications not related to postoperative underlying disease including PTE, MI, CVA 5- Concomitant diseases such as diabetes, heart and lung failure

Design outcomes

Primary

MeasureTime frame
Complications of early ileostomy closure. Timepoint: 1?2?3?4?5?14?30?90?180 day. Method of measurement: questionnaire.;Survival of patients. Timepoint: 3,6,12 month. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Rahimpour

Tehran University of Medical Sciences

Dr.rahimpour83@gmail.com+98 21 6312 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 11, 2026